source
- Kodiak Sciences' Zenkuda shows non-inferior six-month dosing vs Eylea, shares doubleFour years ago Kodiak Sciences saw its share price plunge about 80% after its lead eye-disease candidate failed a head-to-head trial against Regeneron's Eylea, wiping out roughly $2 billion in mark…
- FDA device center outlines FY 2027 guidance agenda, focusing on AI devices and change control plansThe FDA's Center for Devices and Radiological Health announced its guidance priorities for fiscal year 2027 on Oct 1. The top items are finalizing guidance on artificial intelligence‑enabled medic…